The in vivo effects of antimicrobial agents against Toxoplasma gondii were evaluated in mice that were infected intraperitoneally with 104 tachyzoites of the RH strain by determination of survival rates and study of the kinetics of growth of T. gondi in infected mice. At various intervals after infection, subcultures of serial dilutions of blood, lung, and brain homogenates were performed in fibroblast tissue cultures for determination of parasitic loads. Pyrimethamine (18.5 mg/kg per day), sulfadiazine (375 mg/kg per day), and clindamycin (300 mg/kg per day) were administered for 10 days from day 1 or day 4 after infection. Untreated control mice died within 9 days and showed early and predominant lung involvement. All mice treated with sulfadiazine administered from day 1 survived and were apparently healthy; parasitic loads decreased early after treatment, but a relapse was observed 5 days after the cessation of therapy. When pyrimethamine was administered from day 1, 7 of 11 mice died within 25 days; by determination of parasitic loads, the effect of pyrimethamine was only demonstrable from day 6, and a relapse was constantly observed after the cessation of therapy. When pyrimethamine and sulfadiazine were administered in combination, 100% of mice survived; when therapy was started at day 1, parasites remained undetectable; in mice treated from day 4, parasites were eradicated by day 8 but infection relapsed 8 days after the cessation of therapy. All mice treated with clindamycin from day 1 or day 4 died within 10 days, but parasitemia was always undetectable. These results indicate that study of the kinetics of parasitic loads in blood and organs may provide additional information on the effect of antimicrobial agents against T. gondii in regard to the evolution of the infection and may represent a reliable basis for the determination of therapeutic regimens in humans.
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In vivo experimental studies of Toxoplasma gondii are usually performed in mice that are either acutely infected by intraperitoneal injection of tachyzoites or chronically infected by peroral ingestion or intraperitoneal injection of cysts. Another alternative, which better fits with the pathophysiology of toxoplasmosis in immunocompromised human patients, is to induce a reactivation in chronically infected mice by depleting the CD4+ lymphocyte subpopulation (19) , administering anti-gamma interferon (18) , or creating a model of intracerebral infection by local injection of tachyzoites (11, 12) . Assessment of the efficacy of antimicrobial agents is based on the comparative study of mean survival times of untreated and treated mice, enumeration of brain cysts, and in some cases, histologic examination of organs and subinoculation to mice of dilutions of organ homogenates. The survival rate is an important parameter which can be determined easily but which is poorly informative regarding the mode of drug action. Since additional histological studies and mice subinoculations are time-consuming and may not be applied for extensive studies, we proposed the use of a tissue culture method for evaluating the kinetics of growth of T. gondii in infected mice. For Sensitivity of the culture method. The sensitivity of the culture method and the potential effect of the antimicrobial agents that were present in ground tissue were examined in a separate experiment. Five groups of five mice each were used; one group was not treated and four groups were treated for 3 days with pyrimethamine, sulfadiazine, clindamycin, and pyrimethamine combined with sulfadiazine by using the same posology described above. Mice were sacrificed, and then 106 freshly harvested tachyzoites were added to each blood, lung, and brain preparation. Homogenates were prepared and then serialy diluted, and 40 IlI of each dilution was inoculated into tissue culture and then cultivated for 72 h. Cultures were examined for T. gondii by immunofluorescence as described above, and reciprocal titers were recorded for each organ. The sensitivity of the tissue culture method was estimated by comparing the final titer in the culture with the inoculum of 106 parasites that was added to the preparations. The effect of the tissue preparation and the carry-over effect of each drug were examined by a two-way analysis of variance (17) . RESULTS Determination of parasitic loads. Inoculation of serial dilutions of blood and organ homogenates into the cultures did not destroy the monolayers, even at the first dilution of 1/100. By immunofluorescence, parasitic foci were easily observed at a magnification of x 100; with heavily infected organs, these foci were confluent at the first dilution, but monolayers were preserved.
In the experiment in which 106 tachyzoites were added to blood and tissue preparations, no significant difference of sensitivity was observed because of the organ factor (P > 0.1). Mean reciprocal titers were 5.49 + 0.16 log units in blood, 5.46 + 0.19 log units in lungs, and 5.43 + 0.16 log units in brain. These results indicate that the tissue culture method allows for the demonstration of less than 10 parasites in these preparations. In mice that were treated for 3 days, no significant differences because of any treatment factor were observed for blood, lungs, and brain (P > 0.1).
Results of the different experiments with infected mice are given in Fig. 1 to 5. For each date of testing of controls, the logarithms ± standard errors of the mean of the parasitic load determined from the individual value from five group B mice are presented. Survival rates. The survival rates for the different group A mice (estimated by the Kaplan Meier product limit method) are presented in Fig. 6 .
Kinetics of infection in untreated mice. The mean survival time was 7 days in group A mice (Fig. 6) . Parasitic loads were determined in group B mice on days 2, 4, and 6 (Fig. 1 When pyrimethamine and sulfadiazine were administered in combination, all group A mice survived by day 30 after challenge ( Fig. 6) . Parasitic loads were determined in group B mice on days 2, 4, 6, 8, 15, 21, 25, and 32. When therapy was administered from day 1, parasites remained undetectable throughout the follow-up period (data not shown). In mice treated from days 4 to 13, parasites were eradicated on day 8 and remained undetectable until day 21. On day 21, parasites were found in the lungs of one mouse, and then on day 32 parasites were found in the lungs of three mice and in the brains of two mice, with increasing parasitic loads from days 21 to 32. Blood remained negative for parasites during this period (Fig. 4) .
All group A mice treated with clindamycin on day 1 died within 20 days (Fig. 6) . In group B mice, parasitic loads were determined on days 2, 4, 6, 8, and 9 (Fig. 5) . Parasitemia was always undetectable, whereas the parasitic infection progressively involved lungs and brain tissues. On day 8, parasitic loads in lungs and brains were 5.5 ± 0.3 and 3.6 ± 0.2 log units, respectively. In mice treated from day 4, the mean survival time was 8 days (Fig. 6) . Parasitic loads could be determined only on days 6 and 7 (data not shown). On day 6, parasitic loads in lungs and brains were 5.8 ± 0.1 and 3.8 + 0.1 log units, respectively. DISCUSSION Numerous studies have examined the in vivo effect of antimicrobial agents in experimental toxoplasmosis, but discrepant results are often reported, mainly in relation to differences in the experimental procedures of drug administration and variations of the virulence of Toxoplasma strains according to the inoculum and mode of infection (2, 10, 13) .
In this study, we chose to use a model of acute infection with a constantly highly virulent strain of T. gondii (RH strain) and a susceptible Swiss Webster mouse strain. The intraperitoneal route of administration with a large number of parasites (104 tachyzoites), which produces a constantly lethal infection, is also a guarantee of reproducibility for such a study. This mode of infection is not natural and differs from the reactivations which are observed in immunocompromised patients; however, we considered this model to be relevant for the study of the effect of antimicrobial agents in this situation, as determinations of parasitic loads were performed in organs which are most commonly involved in severe toxoplasmosis in humans.
The subculture method was found to be much easier to perform than subinoculation to mice, since several hundred cultures can be performed simultaneously. This allowed the determination of parasitic loads over a wide range of dilutions of blood and organs. By immunofluorescence, parasitic foci were readily identified in the cultures for determination of endpoint dilution titers and parasitic loads. The sensitivity of this method for the demonstration of T. gondii was found to be less than 10 parasites in blood and tissue homogenates, with there being no effect of the antimicrobial agents that were present in the ground tissue. The repeated experiments in control mice showed that the kinetics of development of parasitic disease were reproducible under our experimental conditions and were characterized by an early and predominant lung involvement; this was followed by a more progressive increase of parasitic loads in brain. Blood parasitemia was constantly at a lower level, which indicated the early and predominant tissue affinity of the parasite.
The determination of parasitic loads in treated mice was more informative of the mode of action of antimicrobial agents than the determination of survival rates. When clindamycin was administered from day 1 after infection, the mean survival time was prolonged compared with that in control mice. The determination of parasitic loads in clindamycin-treated mice showed a more progressive increase of the parasitism in lungs and brains compared with those in the controls, whereas parasitemia was undetectable throughout the follow-up period. The disappearance of parasitemia in chronically infected mice treated with clindamycin has already been observed by Araujo and Remington (1); however, in our experiment, none of the mice treated from days 1 and 4 survived, which is in contrast to the lower mortality observed by other investigators in murine models of acute infection (1, 12, 16) . Such differences may be related to the fact that in those studies, treatment was started immediately after infection, whereas we administered clindamycin 1 or 4 days after infection. Despite the early administration of clindamycin, Araujo and Remington (1) and Hofflin and Remington (12) noticed that parasites were not eradicated from the organs; our results also showed that clindamycin does not inhibit the spread of infection in tissues and confirmed that this drug is more suppressive than curative. Since the pharmacokinetic data in mice show that this drug has a large diffusion and high concentrations in tissues, the poor efficacy in a model of acute infection is probably related to the low inhibitory effect of this drug on the parasite or to the fact that concentrations which have been found to be inhibitory in vitro (7) are not achieved in mice with daily administration of 300 mg/kg.
All mice treated with sulfadiazine (375 mg/kg per day) from day 1 survived and could be considered cured based on survival rates. Determination of parasitic loads showed an important decrease of lung involvement after the initiation of therapy, which indicated the early efficacy of this drug, but an increase in parasitic loads was noted at the first determination after the cessation of the treatment. Until the end of the follow-up period, mice were apparently healthy, but parasites were demonstrated at low levels in the brains and lungs of some mice 20 days after the cessation of therapy, whereas parasitemia was always undetectable.
When pyrimethamine was administered from day 1, the inhibitory effect was only demonstrable from day 6, indicating a latency in the in vivo effect of this drug. Parasitic loads decreased thereafter, but a relapse was constantly observed early after the cessation of therapy and there were high parasitic loads in brain and lungs, which may explain the delayed time of death in 40% of the mice.
Compared with sulfadiazine, pyrimethamine alone was found to have a lower efficacy in our model. This observation is surprising since in vitro studies have demonstrated that pyrimethamine is inhibitory at very low concentrations and is probably parasiticidal, whereas sulfadiazine is considered to be parasitostatic (5) . However, these data can be interpreted in view of the pharmacokinetics of this drug in mice, in which pyrimethamine has a very short half-life (4.6 to 5.6 h) and accumulates in tissues within 7 days (4). This may explain the delay in response to therapy and the early occurrence of the relapses after the cessation of therapy. In contrast, the early efficacy of sulfadiazine could be related to its longer half-life in mice (11 h) and a large diffusion in tissues (3) .
When pyrimethamine and sulfadiazine were administered in combination, 100% of mice survived, whether treatment was started at day 1 or 4, which confirms the high synergistic activities of these drugs (8, 9) . When treatment was started early after infection, mice were considered cured, since parasites were always undetectable in blood, lungs, and brain. In contrast, when treatment was started on day 4, i.e., when the parasitic infection already involved blood and organs, a dramatic decrease in the parasitic loads was observed, but relapses occurred after the cessation of therapy. The occurrences of such relapses has been reported previously by Eyles and Coleman (9) in mice treated with sulfadiazine and pyrimethamine. By determination of parasitic loads, we demonstrated that relapses occurred early after the cessation of therapy, even when mice were apparently healthy, and involved brain and lungs, whereas parasitemia was undetectable. In our model, the formation and de novo rupture of cysts cannot be proposed as an explanation for these relapses, since cysts are usually not obtained with the RH strain and cysts could not be formed within the short period of this study. Moreover, Swiss Webster mice are not immunocompromised and chronic infections are not reactivated spontaneously. The main explanation for the relapses that we observed in organs of mice treated with sulfadiazine, pyrimethamine, and combinations of the two drugs is probably the escape of some parasites in organs in which inhibitory concentrations of drugs may not be achieved. This observation may justify the need for maintenance of long periods of therapy in humans and indicates that complementary studies are needed to better determine the tissue pharmacokinetics of these drugs in animals and humans in correlation with the distribution of T. gondii in tissues following an acute infection.
Finally, results of this study indicate that the kinetic study of parasitic loads in several organs of infected animals is a determinant for the assessment of drug efficacy since the evidence of parasitic relapse can be characterized by this method and may modify the usual therapy which can be proposed in humans.
